Related Experiment Video
Updated: Aug 2, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis
Fieke W Hoff1,2, Prapti A Patel1,2, Andrew J Belli3
1Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract:
Venetoclax (VEN) in combination with hypomethylating agents (HMA) or low-dose cytarabine has become the standard of care for patients with acute myeloid leukemia (AML) who are ineligible to receive intensive induction chemotherapy. Clinical trials are performed in a controlled setting that can be difficult to emulate in the real world. We sought to investigate outcomes of patients treated with VEN-based therapy in the real world. Patients with an age of ≥65 years who received frontline VEN-based therapy were identified using the COTA database (n = 112). The majority of patients (91%) were treated in the community setting and had adverse-risk AML (63%). The real-world overall response rate (rwORR) was 55% with a median real-world overall survival (rwOS) of 13 months after VEN/HMA. The rwORR was lower and median rwOS was shorter than those reported in the VIALE-A trial, underscoring the importance of studying novel therapies using real-world data.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Related Concept Videos
Clinical Trials: Overview
Treatment Resistant Cancers
Cancer Survival Analysis
Clinical Trials
There are four phases in a clinical trial. A phase one...
Analysis of Population Pharmacokinetic Data
Venous Thrombosis III: Interprofessional Care